Furthermore, IL-6R inhibitors Sarilumab and Tocilizumab were also shown to be beneficial for COVID-19 patients and were recommended for use in hospitalized patients who require supplemental oxygen, high-flow oxygen, non-invasive ventilation, or invasive mechanical ventilation by NIH COVID-19 Treatment Guidelines. The gene discussed is IL6R; the disease is COVID-19.